<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article126</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PARADIGM-HF" style="display:block; margin-bottom:10px;">PARADIGM-HF Original</a></li>
<h2><strong>PARADIGM-HF</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    LCZ696 versus Enalapril in Heart Failure. The New England Journal of Medicine. 2014.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the angiotensin receptor–neprilysin inhibitor LCZ696 confer a survival benefit over enalapril in patients with heart failure and a reduced ejection fraction?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
LCZ696, compared to enalapril, reduced the risks of cardiovascular death and hospitalization for heart failure in patients with heart failure and reduced ejection fraction.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff date, LCZ696 (sacubitril/valsartan) may be considered in place of ACE inhibitors to further reduce the risks of morbidity and mortality in patients with heart failure with reduced ejection fraction.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, controlled trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
8,442 patients with NYHA class II, III, or IV heart failure and an ejection fraction of ≤40%.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized to LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, with the trial designed to detect a difference in rates of death from cardiovascular causes.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
- LCZ696 group saw a primary outcome event in 21.8% vs. 26.5% in the enalapril group (HR 0.80; 95% CI, 0.73 to 0.87; P&lt;0.001).<br/>
- Death from cardiovascular causes occurred in 17.0% on LCZ696 vs. 19.8% on enalapril (HR 0.84; 95% CI, 0.76 to 0.93; P&lt;0.001).<br/>
- Hospitalization for heart failure was also 21% lower in the LCZ696 group (P&lt;0.001).<br/>
- Improved symptoms and physical limitations associated with heart failure in the LCZ696 group (P=0.001).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
While LCZ696 had higher rates of hypotension and nonserious angioedema, it had lower rates of renal impairment, hyperkalemia, and cough compared to the enalapril group.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was funded by Novartis.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The full text article was published in The New England Journal of Medicine, 2014, and is available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
